Artículo Original 95 CONSENSO CHILENO DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILE - C. Hernández-Rocha et al. micina, podría ser una alternativa en la tercera recurrencia. El manejo de la DACD recurrente se resume en la Tabla 5. En conclusión, presentamos el primer consenso chileno en el manejo de la DACD que abarca aspectos de prevención, diagnóstico y tratamiento. La difusión y aplicación de esta guía clínica debería impactar en un mejor manejo de los pacientes con DACD y fomentar la investigación en esta importante y costosa enfermedad. Referencias 1.- Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-9. 2.- Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011; 32: 387-90. 3.- Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62. 4.- Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36. 5.- Barra-Carrasco J, Hernández-Rocha C, Ibáñez P, Guzmán-Durán AM, Álvarez-Lobos M, Paredes-Sabja D. Clostridium difficile spores and its relevance in the persistence and transmission of the infection. Rev Chilena Infectol 2014; 31: 694-703. 6.- Gerding DN, Muto CA, Owens RC, Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S43-9. 7.- Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-49. 8.- Aguayo C, Flores R, Levesque S, Araya P, Ulloa S, Lagos J, et al. Rapid spread of Clostridium difficile NAP1/027/ST1 in Chile confirms the emergence of the epidemic strain in Latin America. Epidemiol Infect 2015: 143 (14): 3069-73. 9.- Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012; 18 Suppl 6: 5-12. 10.- Balassiano IT, Yates EA, Domingues RM, Ferreira EO. Clostridium difficile: a problem of concern in developed countries and still a mystery in Latin America. J Med Microbiol 2012; 61: 169-79. 11.- Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2 (8358): 1043-6. 12.- Hernández-Rocha C, Naour S, Álvarez- Lobos M, Paredes-Sabja D. Clostridium difficile associated infections: an updated view. Rev Chilena Infectol 2012; 29: 434-45. 13.- Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo V G, Mcdonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55. 14.- Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-98; quiz 499. 15.- Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26. 16.- Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. Br Med J 2008; 336: 1049-51. 17.- Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, et al. What is "quality of evidence" and why is it important to clinicians? Br Med J 2008; 336: 995-8. 18.- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008; 336: 924-6. 19.- Hasson F, Keeney S, McKenna HP. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32: 1008-15. 20.- Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. Br Med J 2008; 336: 2-3. 21.- Reimer C. Safety of long-term PPI therapy. Best practice & research. Clin Gastroenterol 2013; 27: 443-54. 22.- Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother 2006; 50: 3901-4. 23.- Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 2007; 51: 2883-7. 24.- Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 4133-7. 25.- Altman KW, Chhaya V, Hammer ND, Pavlova S, Vesper BJ, Tao L, et al. Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Gastroenterol. latinoam 2016; Vol 27, Nº 2: 79-100
gastro 2 2016
To see the actual publication please follow the link above